|
|||
| CrossRef Text and Data Mining | |||
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. | |||
| A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder | |||
| Jung Hyun Shin, Seong Jin Jeong, Sun-Ouck Kim, Cheol Young Oh, Kyung Jin Chung, Dong Gil Shin, Tae Hyo Kim, Joonbeom Kwon, Ju-Hyun Shin, Woong Jin Bae, Kyu-Sung Lee, Myung-Soo Choo | |||
|
Int Neurourol J. 2023;27(2):106-115. Published online 2023 June 30 DOI: https://doi.org/10.5213/inj.2346022.011 |
|||
|
A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder International Neurourology Journal. 2023;27(2):106-115  Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Multicenter Study Yearbook of Urology. 2010;2010:36-37 Editorial Comment to Efficacy of novel β3‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study International Journal of Urology. 2018;26(3):375-376 Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study European Urology. 2018;73(5):783-790 Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial Yearbook of Urology. 2011;2011:25-26 Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: A randomized, double-blind, placebo-controlled phase 3 study European Urology Supplements. 2018;17(2):e1531-e1532 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder Yearbook of Urology. 2014;2014:68-69 Re: Chen et al.: Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial (Urology 2017;100:59-64) Urology. 2017;102:267 The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials International Urogynecology Journal. 2023;34(9):2207-2216 Efficacy and Safety of the Selective β3
-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study LUTS: Lower Urinary Tract Symptoms. 2014;7(2):84-92 |
